Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Medical Disposables Market

ID: MRFR/MED/50872-HCR
200 Pages
Nidhi Mandole
Last Updated: February 06, 2026

UK Medical Disposables Market Research Report By Product (Wound Management Products, Drug Delivery Products, Diagnostic and Laboratory Disposables, Dialysis Disposable, Incontinence Products, Respiratory Supplies, Sterilization Supplies, Non-woven Disposables, Disposable Masks, Disposable Eye Gear, Disposable Gloves, Hand Sanitizers, Others), By Raw Material (Plastic Resin, Nonwoven Material, Rubber, Paper and Paperboard, Metals, Glass, Others) and By End Use (Hospitals, Home Healthcare, Outpatient/Primary Care Facilities, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Medical Disposables Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Pharmaceutical, BY Product (USD Billion)
  49.     4.1.1 Wound Management Products
  50.     4.1.2 Drug Delivery Products
  51.     4.1.3 Diagnostic and Laboratory Disposables
  52.     4.1.4 Dialysis Disposable
  53.     4.1.5 Incontinence Products
  54.     4.1.6 Respiratory Supplies
  55.     4.1.7 Sterilization Supplies
  56.     4.1.8 Non-woven Disposables
  57.     4.1.9 Disposable Masks
  58.     4.1.10 Disposable Eye Gear
  59.     4.1.11 Disposable Gloves
  60.     4.1.12 Hand Sanitizers
  61.     4.1.13 Others
  62.   4.2 Pharmaceutical, BY Raw Material (USD Billion)
  63.     4.2.1 Plastic Resin
  64.     4.2.2 Nonwoven Material
  65.     4.2.3 Rubber
  66.     4.2.4 Paper and Paperboard
  67.     4.2.5 Metals
  68.     4.2.6 Glass
  69.     4.2.7 Others
  70.   4.3 Pharmaceutical, BY End Use (USD Billion)
  71.     4.3.1 Hospitals
  72.     4.3.2 Home Healthcare
  73.     4.3.3 Outpatient/Primary Care Facilities
  74.     4.3.4 Others
  75. 5 SECTION V: COMPETITIVE ANALYSIS
  76.   5.1 Competitive Landscape
  77.     5.1.1 Overview
  78.     5.1.2 Competitive Analysis
  79.     5.1.3 Market share Analysis
  80.     5.1.4 Major Growth Strategy in the Pharmaceutical
  81.     5.1.5 Competitive Benchmarking
  82.     5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  83.     5.1.7 Key developments and growth strategies
  84.       5.1.7.1 New Product Launch/Service Deployment
  85.       5.1.7.2 Merger & Acquisitions
  86.       5.1.7.3 Joint Ventures
  87.     5.1.8 Major Players Financial Matrix
  88.       5.1.8.1 Sales and Operating Income
  89.       5.1.8.2 Major Players R&D Expenditure. 2023
  90.   5.2 Company Profiles
  91.     5.2.1 Medtronic (US)
  92.       5.2.1.1 Financial Overview
  93.       5.2.1.2 Products Offered
  94.       5.2.1.3 Key Developments
  95.       5.2.1.4 SWOT Analysis
  96.       5.2.1.5 Key Strategies
  97.     5.2.2 Johnson & Johnson (US)
  98.       5.2.2.1 Financial Overview
  99.       5.2.2.2 Products Offered
  100.       5.2.2.3 Key Developments
  101.       5.2.2.4 SWOT Analysis
  102.       5.2.2.5 Key Strategies
  103.     5.2.3 Baxter International (US)
  104.       5.2.3.1 Financial Overview
  105.       5.2.3.2 Products Offered
  106.       5.2.3.3 Key Developments
  107.       5.2.3.4 SWOT Analysis
  108.       5.2.3.5 Key Strategies
  109.     5.2.4 Cardinal Health (US)
  110.       5.2.4.1 Financial Overview
  111.       5.2.4.2 Products Offered
  112.       5.2.4.3 Key Developments
  113.       5.2.4.4 SWOT Analysis
  114.       5.2.4.5 Key Strategies
  115.     5.2.5 3M (US)
  116.       5.2.5.1 Financial Overview
  117.       5.2.5.2 Products Offered
  118.       5.2.5.3 Key Developments
  119.       5.2.5.4 SWOT Analysis
  120.       5.2.5.5 Key Strategies
  121.     5.2.6 Smith & Nephew (GB)
  122.       5.2.6.1 Financial Overview
  123.       5.2.6.2 Products Offered
  124.       5.2.6.3 Key Developments
  125.       5.2.6.4 SWOT Analysis
  126.       5.2.6.5 Key Strategies
  127.     5.2.7 B. Braun Melsungen AG (DE)
  128.       5.2.7.1 Financial Overview
  129.       5.2.7.2 Products Offered
  130.       5.2.7.3 Key Developments
  131.       5.2.7.4 SWOT Analysis
  132.       5.2.7.5 Key Strategies
  133.     5.2.8 Halyard Health (US)
  134.       5.2.8.1 Financial Overview
  135.       5.2.8.2 Products Offered
  136.       5.2.8.3 Key Developments
  137.       5.2.8.4 SWOT Analysis
  138.       5.2.8.5 Key Strategies
  139.     5.2.9 Terumo Corporation (JP)
  140.       5.2.9.1 Financial Overview
  141.       5.2.9.2 Products Offered
  142.       5.2.9.3 Key Developments
  143.       5.2.9.4 SWOT Analysis
  144.       5.2.9.5 Key Strategies
  145.   5.3 Appendix
  146.     5.3.1 References
  147.     5.3.2 Related Reports
  148. 6 LIST OF FIGURES
  149.   6.1 MARKET SYNOPSIS
  150.   6.2 UK MARKET ANALYSIS BY PRODUCT
  151.   6.3 UK MARKET ANALYSIS BY RAW MATERIAL
  152.   6.4 UK MARKET ANALYSIS BY END USE
  153.   6.5 KEY BUYING CRITERIA OF PHARMACEUTICAL
  154.   6.6 RESEARCH PROCESS OF MRFR
  155.   6.7 DRO ANALYSIS OF PHARMACEUTICAL
  156.   6.8 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
  157.   6.9 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
  158.   6.10 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
  159.   6.11 PHARMACEUTICAL, BY PRODUCT, 2024 (% SHARE)
  160.   6.12 PHARMACEUTICAL, BY PRODUCT, 2024 TO 2035 (USD Billion)
  161.   6.13 PHARMACEUTICAL, BY RAW MATERIAL, 2024 (% SHARE)
  162.   6.14 PHARMACEUTICAL, BY RAW MATERIAL, 2024 TO 2035 (USD Billion)
  163.   6.15 PHARMACEUTICAL, BY END USE, 2024 (% SHARE)
  164.   6.16 PHARMACEUTICAL, BY END USE, 2024 TO 2035 (USD Billion)
  165.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  166. 7 LIST OF TABLES
  167.   7.1 LIST OF ASSUMPTIONS
  168.     7.1.1
  169.   7.2 UK MARKET SIZE ESTIMATES; FORECAST
  170.     7.2.1 BY PRODUCT, 2025-2035 (USD Billion)
  171.     7.2.2 BY RAW MATERIAL, 2025-2035 (USD Billion)
  172.     7.2.3 BY END USE, 2025-2035 (USD Billion)
  173.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  174.     7.3.1
  175.   7.4 ACQUISITION/PARTNERSHIP
  176.     7.4.1

UK Pharmaceutical Market Segmentation

Pharmaceutical By Product (USD Billion, 2025-2035)

  • Wound Management Products
  • Drug Delivery Products
  • Diagnostic and Laboratory Disposables
  • Dialysis Disposable
  • Incontinence Products
  • Respiratory Supplies
  • Sterilization Supplies
  • Non-woven Disposables
  • Disposable Masks
  • Disposable Eye Gear
  • Disposable Gloves
  • Hand Sanitizers
  • Others

Pharmaceutical By Raw Material (USD Billion, 2025-2035)

  • Plastic Resin
  • Nonwoven Material
  • Rubber
  • Paper and Paperboard
  • Metals
  • Glass
  • Others

Pharmaceutical By End Use (USD Billion, 2025-2035)

  • Hospitals
  • Home Healthcare
  • Outpatient/Primary Care Facilities
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓